Alpheus Medical opens enrollment in new clinical trial for butterfly glioblastoma
Alpheus Medical has opened enrollment in a clinical trial evaluating its sonodynamic therapy in butterfly glioblastoma.
Alpheus Medical
Private
Chanhassen, Minnesota-based clinical-stage oncology company developing a sonodynamic therapy platform that combines low-intensity diffuse ultrasound with oral 5-aminolevulinic acid for solid tumors, with an initial focus on glioblastoma.
Company Info
Sector:Oncology — Medical Devices and Therapeutics
Headquarters:Chanhassen, Minnesota, USA
Founded:2014
Website:alpheusmedical.com/
Funding Round:Series B
Total Funding:~$68M
Funding & Investor Relations
Notable Investors
- OrbiMed
- HealthQuest Capital
- Action Potential Venture Capital
Upcoming Milestones & Key Dates
2026-H2
clinical
Enrollment in butterfly glioblastoma clinical trial
Clinical Development Pipeline
ALP-101 (sonodynamic therapy)
Target: Low-intensity diffuse ultrasound with 5-ALARecent News
Leadership Team
Vijay Agarwal
Founder and Chief Executive Officer